They Just Don't Get...
Depomed Inc. (DEPO: NASDAQ)
$5.01 0.01 | 0.20%
06/04/12 - 12:14 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 70.73M | 3.90M | -22.01M | -15.30M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -6.21M | -1.41M | -1.26M | -51.00K |
| (Increase) Decrease in Inventories | -3.82M | 995.00K | 283.00K | 415.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | -145.00K | 4.22M | -2.99M |
| (Decrease) Increase In Payables | 7.81M | 3.08M | 2.48M | 6.06M |
| (Decrease) Increase In Other Current Liabilities | 597.00K | 234.00K | -197.00K | 1.04M |
| (Increase) Decrease In Other Working Capital | -11.71M | -11.49M | 14.85M | 10.57M |
| Other Non-Cash Items | 3.87M | 2.03M | 2.66M | 2.45M |
| Net Cash From Continuing Operations | 57.65M | -2.38M | 1.84M | 3.35M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 57.65M | -2.38M | 1.84M | 3.35M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 133.67M | 72.02M | 149.32M | 96.74M |
| Purchases of Property, Plant & Equipment | -698.00K | -179.00K | -629.00K | -257.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -195.16M | -71.32M | -144.57M | -101.61M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -62.19M | 512.00K | 4.13M | -5.12M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 9.40M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 8.30M | 1.42M | 2.04M | 441.00K |
| Repayment of Long-Term Debt | -2.24M | -3.84M | -3.31M | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | -316.00K |
| Net Cash From Financing Activities | 6.05M | -2.43M | -1.27M | 9.52M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 1.52M | -4.30M | 4.69M | 7.75M |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
- Usergbwineman Portfolio 1
- UserLTR7181 Portfolio 1
- Userfrankie'spicks
Latest DEPO Headlines from TheStreet
- Stocks Under $10: Healthcare Name on Sale
05.17.12 | 07:05 am - Depomed: After-Hours Trading 02.03.12 | 05:02 pm
- Depomed Stock Hits New 52-Week Low (DEPO) 10.18.11 | 10:10 am
- Depomed Stock Gaps Down On Today's Open (DEPO) 10.14.11 | 09:10 am
- 7 Stocks to Watch: Google, Apple 10.14.11 | 07:10 am
- Google, Depomed: After-Hours Trading 10.13.11 | 05:10 pm
- Acadia Pharmaceuticals: Investing With No Safety Net 06.24.11 | 10:06 am
- Biotech Stock Mailbag: Star Scientific 03.18.11 | 07:03 am
- 5 Stocks to Watch: Sanmina, UBS 03.17.11 | 07:03 am
- Guess?, DepoMed: After-Hours Trading 03.16.11 | 05:03 pm
Press Releases for DEPO
- Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf - PR Newswire 05.29.12 | 08:05 am
- Depomed To Present At Jefferies 2012 Global Health Care Conference - PR Newswire 05.25.12 | 08:05 am
- Depomed To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - PR Newswire 05.10.12 | 08:05 am
- New 60,000 Square Foot Lease At The Pacific Research Center Signed By Biomed Realty And Depomed - PR Newswire 04.09.12 | 04:04 pm
- Santarus And Depomed Announce Settlement With Lupin Of GLUMETZA Patent Litigation - Business Wire 02.22.12 | 04:02 pm
- Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products - Business Wire 08.22.11 | 05:08 am
- Ironwood Pharmaceuticals And Depomed Announce Collaboration, Research And License Agreement - Business Wire 07.27.11 | 04:07 pm
- Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets - Business Wire 01.05.11 | 04:01 am
- New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA - PR Newswire 06.28.10 | 08:06 am
- Depomed To Present At The 9th Annual JMP Securities Research Conference - Business Wire 05.04.10 | 08:05 am
Partner Headlines for DEPO
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
- Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise - Benzinga 01.23.12 | 04:01 pm
- BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps - Seeking Alpha 10.16.11 | 08:10 am
- UPDATE: Zacks Upgrades DepoMed from Neutral to Outperform - Benzinga 08.10.11 | 09:08 am
- 5 Highly Profitable Stocks Undervalued by EPS Trends - Seeking Alpha 07.11.11 | 06:07 am
- Contrarian Ideas: 25 High Growth Stocks With Significant Short Selling - Seeking Alpha 06.06.11 | 08:06 am





